Here's the intro from the web page...looking good:
A Brief Message from SciClone's President and CEO
Welcome to our new web site - sciclone.com.
Our site is divided into six major categories: Corporate, News Room,
ZADAXIN®, CPX, Investor Relations and Request Info. Our site map
can guide you throughout our web site.
Our site will help you to better understand SciClone's mission,
strategy and solid business fundamentals. I am proud that we are one
of about 10% of publicly traded biopharmaceutical companies directly
selling a developed drug and one of an ever smaller number of
companies marching toward operating profitability by the end of 2000.
SciClone's lead drug, ZADAXIN® thymosin alpha 1, boosts the body's
immune system in the fight against life-threatening diseases such as
hepatitis B, hepatitis C and cancer. ZADAXIN already has been
approved in 16 countries outside the U.S. In the U.S., we expect to
begin phase 2 development of ZADAXIN in hepatitis B and cancer and
phase 3 development for hepatitis C by the end of Q1 2000. CPX, our
promising new protein repair therapy, is currently in phase 2
development for the treatment of cystic fibrosis, the most common
fatal genetic disease in the U.S.
Our site will continue to evolve as a communication vehicle and I hope
that you will regularly visit us and our international web site at
www.scicloneinternational.com to learn more about our company.
Thank you for your interest in SciClone.
Sincerely yours,
Donald R. Sellers
President and Chief Executive Officer - SciClone Pharmaceuticals,
Inc.
Managing Director - SciClone Pharmaceuticals International Ltd. |
